Speeding ticket takeout2 Nov 2019 09:11
1. seeking advice from the FDA regarding future Traumakine development.
2. funded to early 2020
3.renewed its shareholder authorities at the Company's EGM to allow the Company to issue up to 7,871,000 shares.
4. partnering discussions continue
5.investigating dual listing its shares on Nasdaq First North Growth Market. No decisions regarding a dual listing have been made.